Pedersen, Stine Jacobsen and Maggie Fick COPENHAGEN (Reuters) -Investors wiped $70 billion off Novo Nordisk's market value on ...

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...

Novo Nordisk's downward guidance Tuesday sent its stock diving 20%, even as new leadership remains bullish on the company's ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Facing a $70 billion market loss, Novo Nordisk appointed Maziar Mike Doustdar as its new CEO to navigate intensifying ...

In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

The Danish-maker of Wegovy and Ozempic has warned that its full-year sales and profits will not grow as quickly as expected ...

Novo Nordisk's newly appointed CEO, Maziar Mike Doustdar, confronts the daunting task of revitalizing the company's declining sales and share prices. Despite investor skepticism due to his lack of U.S ...

Novo Nordisk stock (ticker: NVO) fell after the drugmaker unexpectedly cuts its full-year guidance, citing lower sales ...

The biggest fallers on the FTSE 100 were Croda International, down 301.00p at 2,598.00p, Rentokil Initial, down 12.90p at 348.10p, Glencore, down 10.80p at 305.90p, Unite Group, down 21.50p at 764.50p ...